Table 5.

A comparison of United States VAERS reports during five consecutive influenza seasons, 2006/2006 through 2010/2011.

Season and vaccine (July–June)	All VAERS reports	All influenza reportsa	VAERS female influenza reportsb	% of VAERS female influenza reports (100•B/A)	No. of fetal-loss reports to VAERS
2006/2007 TIV	20,502	3123	2048	65.6	–c
2007/2008 TIV	26,117	4205	2654	63.1	4
2008/2009 TIV	22,579	5707	3529	61.8	5d
2009/2010 A-H1N1	32,877	12,300e	7734f	62.9	170g
2009/2010 TIV		7671 e	4863 f	63.4	22g
2010/2011 TIV	23,416	9602	6372	66.4	21

Note: The bold figures show existing trends for the Trivalent Influenza Vaccine (TIV) over several years and should not be confused with the figures for the special 2-dose 2009/10 Influenza season which includes the unique, separate dose of A-H1N1. Also, linear regression analysis was run on the figures shown in bold to show statistical correlation and annual existing trends in TIV reports. VAERS: Vaccine Adverse Event Reporting System; TIV: trivalent inactivated influenza vaccine.

^aAll influenza adverse reports for TIV by year demonstrate linear correlation (figures in blue), r ² = 0.99.

^bFemale influenza adverse reports for TIV by year demonstrate a linear correlation (figures in blue), r ² = 0.97.

^cNot Reviewed.

^dIncludes one live virus–related fetal death.

^eFor 2009/2010, the combined A-H1N1 and TIV influenza reports total 19,971; however, 1105 duplicate reports must be deducted due to patients reporting receipt of both TIV and A-H1N1, yielding 18,866.

^fFor 2009/2010, the combined A-H1N1 and TIV female influenza reports total 12,597; however, 536 duplicate reports must similarly be deducted, yielding 12,061.

^gFigure includes 18 VAERS fetal-loss reports specifying receipt of both A-H1N1 vaccine and TIV.